Hiromi Muta
Overview
Explore the profile of Hiromi Muta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sun X, Yamada H, Shibata K, Muta H, Tani K, Podack E, et al.
J Immunol
. 2010 Nov;
185(12):7671-80.
PMID: 21068411
We have previously found that CD30 ligand (CD30L; CD153)/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation, at least partly via downregulation of...
12.
Sun X, Yamada H, Shibata K, Muta H, Tani K, Podack E, et al.
J Immunol
. 2010 Jul;
185(4):2222-30.
PMID: 20639486
A CD30 ligand (CD30L; CD153) and its receptor, CD30, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily. These were expressed preferentially by activated CD4(+)T cells. In...
13.
Muta H, Ishii M
J Pediatr
. 2010 Mar;
157(1):120-6.
PMID: 20304414
Objective: To compare the long-term efficacy of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for stenotic lesions after Kawasaki disease. Study Design: Questionnaires were sent to pediatricians...
14.
Muta H, Ishii M, Iemura M, Matsuishi T
J Pediatr
. 2009 Dec;
156(3):439-43.
PMID: 19969307
Objective: To investigate the health-related quality of life (HRQOL) in adolescents and young adults with Kawasaki disease (KD). Study Design: We conducted a cross-sectional observational study. Patients were eligible for...
15.
Maeda N, Muta H, Oflazoglu E, Yoshikai Y
Cancer Sci
. 2009 Oct;
101(1):224-30.
PMID: 19799612
Adult T-cell leukemia (ATL) is an aggressive malignancy of activated CD4(+) T cells associated with human T-cell leukemia virus type I (HTLV-I) infection. No conventional chemotherapy regimen has appeared successful...
16.
Tang C, Yamada H, Shibata K, Muta H, Wajjwalku W, Podack E, et al.
J Immunol
. 2008 Oct;
181(9):6316-27.
PMID: 18941223
A CD30 ligand (CD30L, CD153) is a type II membrane-associated glycoprotein belonging to the TNF family. To illustrate the potential role of CD30L in CD4(+) Th1 cell responses, we investigated...
17.
Sun X, Somada S, Shibata K, Muta H, Yamada H, Yoshihara H, et al.
Gastroenterology
. 2008 Feb;
134(2):447-58.
PMID: 18242212
Background & Aims: A CD30-ligand (CD30L) is a 40-kilodalton, type II membrane-associated glycoprotein belonging to the tumor necrosis factor family. Serum levels of soluble CD30 increased in inflammatory bowel diseases...
18.
Sugahara Y, Ishii M, Muta H, Iemura M, Matsuishi T, Kato H
Pediatr Cardiol
. 2007 Nov;
29(2):398-401.
PMID: 18027010
We retrospectively investigated the effect of warfarin therapy in improving the clinical outcome of Kawasaki disease (KD) patients with giant coronary aneurysms (GAs). We followed 2350 KD patients from 1973...
19.
Muta H, Ishii M, Iemura M, Suda K, Nakamura Y, Matsuishi T
Circ J
. 2007 Oct;
71(11):1791-3.
PMID: 17965504
Background: The aim of this study was to investigate the effect of a revision of the fever criterion for initial intravenous immunoglobulin (IVIG) treatment, and cardiovascular sequelae, in the new...
20.
Maeda T, Sugano M, Guan J, Oyama J, Higuchi Y, Makino N, et al.
J Neuropsychiatry Clin Neurosci
. 2007 Sep;
19(3):342-3.
PMID: 17827426
No abstract available.